Compare Merck & Co., Inc. (MRK) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Snap Inc — how do they compare? Merck & Co., Inc. trades at $148.23 (market cap $366.28B), while Snap Inc trades at $5.33 (market cap $9.18B). The key difference: Merck & Co., Inc. is far larger — about 39.9× Snap Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| MRK | SNAP | |
|---|---|---|
Market Cap | $366.28B | $9.18B |
Sector | Health | Media |
52-Week High | $156.43 | $9.09 |
52-Week Low | $77.60 | $3.93 |
Enterprise Value | $413.04B | $10.75B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Snap Inc. (SNAP) trades at $5.43, down 0.73% on the day, with a bullish technical signal driven by moving averages and strong operational cash flow growth. The company reported a net loss of $460.49 million in 2025, but revenue grew to $5.93 billion and losses are narrowing year-over-year. Recent news includes the appointment of a new Chief Commercial Officer and ongoing legal challenges related to youth safety.
The outlook remains cautious; while improving financials and a $7.02 analyst price target suggest upside, persistent net losses, high debt, and regulatory lawsuits pose significant risks. Investor sentiment is mixed amid insider selling and legal overhangs, requiring careful risk assessment for potential investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
